The company stock has a Forward Dividend ratio of 0, while the dividend yield is 0. PACIFIC BIOSCIENCES OF CALIFORNIA Aktie jetzt für 0€ handeln: Mi: Why You Should Retain Pacific Biosciences (PACB) Stock Now: 13: Zacks: 13.01. Pacific Biosciences of California Inc. (NASDAQ:PACB) went up by 8.87% from its latest closing price compared to the recent 1-year high of $40.77. Pacific Biosciences of California, Inc.PACB recently announced fourth-quarter 2020 preliminary revenue figures.. With its Forward Dividend at 0 and a yield of 0%, the company’s investors could be worried for the PACB stock to lose ahead of the earnings release. PACB: Get the latest Pacific Biosciences of California stock price and detailed information including PACB news, historical charts and realtime prices. Pacific Biosciences of California Inc. had a pretty favorable run when it comes to the market performance. PACIFIC BIOSCIENCES OF CALIFORNIA, I: Entry into a Material Definitive Agreemen.. 13.01. The stock spiked 12.82% in intraday trading to $41.65 this Wednesday, Jan 20, hitting a weekly high. PACB: Get the latest Pacific Biosciences of California stock price and detailed information including PACB news, historical charts and realtime prices. Analysts covering Pacific Biosciences of California Inc currently have a consensus Earnings Per Share (EPS) forecast of … MENLO PARK, Calif., Sept. 14, 2020 (GLOBE NEWSWIRE) -- Pacific Biosciences of California, Inc. (NASDAQ: PACB), a leading provider of high-quality sequencing of genomes, transcriptomes, and e... Pacific Biosciences (PACB) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes. Pacific Biosciences of California share price volatility. Losses were -$84.13 million, -17.97% less than in 2018. Keith Speights (TMFFishBiz) Oct 2, … Pacific Biosciences of California, Inc. (PACB) CEO Christian Henry on Q3 2020 Results - Earnings Call Transcript. Do the numbers hold clues to what lies ahead for the st... MENLO PARK, Calif., Aug. 03, 2020 (GLOBE NEWSWIRE) -- Pacific Biosciences of California, Inc. (NASDAQ: PACB) today announced financial results for its second quarter ended June 30, 2020. Its single molecule real-time (SMRT) sequencing technology enables single molecule real-time detection of biological processes. Pacific Biosciences of California share dividends. Pacific Biosciences (PACB) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes. At that level they are trading at 39.68% premium to the analyst consensus target price of 0.00. Sign up for free newsletters and get more CNBC delivered to your inbox. Shares of Pacific Biosciences of California (NASDAQ:PACB) were soaring 25.6% as of 11:54 a.m. EDT on Wednesday. Pacific Biosciences of California, Inc. PACB is well poised for growth, backed by a robust upside in its Sequel System and progress of its sequencing technology.However, tough … Investor confidence is high on Pacific Biosciences (PACB) stock, courtesy of solid prospects. Pacific Biosciences of California Inc (PACB) stock is up 13.64% while the S&P 500 is flat 0% as of 2:59 PM on Tuesday, Dec 1. Pacific Biosciences of California, Inc. (Exact name of registrant as specified in its charter) ... Common Stock, par value $0.001 per share. Pacific Biosciences' mission is to transform the way humankind acquires, processes and interprets data from living systems through the design, development and commercialization of innovative tools for biological research.. We have developed a novel approach to studying the synthesis and regulation of DNA, RNA and protein. Using Pacific Bioscience of California machines, scientists in laboratories around the world are able to rapidly and accurately observe DNA in real-time, allowing for access to a full spectrum […] Company Analysis and Financial Data Status. How has Pacific Biosciences of California's share price performed over time and what events caused price changes? If we narrow it down even further, the data shows that none out of 5 analysts rate the stock as a Sell; another but none rate it as Overweight. A Division of NBCUniversal. Cathie Wood's Ark Invest ETF ARKG just added PACB as the highest weighted equity in the portfolio!! It offers The SMRT Cell, Phospholinked nucleotides and The PacBio RS II and Sequel... Cramer's lightning round: I would own Apple, not trade it. What happened. "This is another great stock," Jim Cramer told viewers of the Lightning Round segment of Mad Money Tuesday evening when asked about Pacific Biosciences of California Inc. . Pacific Biosciences (PACB) saw revenue decline in both its operating segments in Q2. Latest Pacific Biosciences of California Inc News. Pacific Biosciences of California, Inc. has a market cap of $7.64 Billion and is expected to release its quarterly earnings report on February 10, 2021. With its Forward Dividend at 0 and a yield of 0%, the company’s investors could be worried for the PACB stock to lose ahead of the earnings release. Comparatively, Bio-Rad Laboratories has a beta of 0.83, indicating that its stock price is 17% less volatile than the S&P 500. The company’s stock price has collected 17.34% of gains in the last five trading sessions. Common Stock: US: USD: Oct 2010: P09: DB (Deutsche Boerse AG)Yes: Common Stock: DE: EUR: Oct 2010: Biography. Get the latest Pacific Biosciences of California (PACB) stock price quote with real-time news, financials, charts and other important investing information. The 1-year high price for the company’s stock is recorded $41.65 on 01/20/21, with the lowest value was $24.47 for the same time period, recorded on 01/04/21. PACB | Complete Pacific Biosciences of California Inc. stock news by MarketWatch. Invest in Pacific Biosciences of California, Inc. stock and others with any dollar amount. Got a confidential news tip? 2020: WALL STREET STOCK EXCHANGE: Les valeurs à suivre à Wall Street: 2020: WALL STREET STOCK EXCHANGE: USA-Les valeurs à suivre à Wall Street (actualisé): 2015: PACIFIC BIOSCIENCES OF CALIFORNIA: stellt neue, auf seiner SMRT-Technologie bas..: 2015: PACIFIC BIOSCIENCES OF CALIFORNIA: lance une nouvelle plate-forme de séquençage..: 2013: PACIFIC BIOSCIENCES OF CALIFORNIA… Pacific Biosciences of California Inc. had a pretty favorable run when it comes to the market performance. Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing systems to resolve genetically complex problems. At that level they are trading at 39.68% premium to the analyst consensus target price of 0.00. You agree to give Pacific Biosciences a credit line as follows: "Courtesy of Pacific Biosciences of California, Inc., Menlo Park, CA, USA" and also include any other credits or acknowledgments noted by Pacific Biosciences. Click here now. With its Forward Dividend at 0 and a yield of 0%, the company’s investors could be worried for the PACB stock to … According to present data Pacific Biosciences of California's PACB shares and potentially its market environment have been in a bullish cycle in the last 12 months (if exists). Investors need to pay close attention to Pacific Biosciences (PACB) stock based on the movements in the options market lately. Data is a real-time snapshot *Data is delayed at least 15 minutes. Relative to other stocks in its sector (Healthcare), Pacific Biosciences Of California Inc has a … PDF Version . Its single molecule real-time (SMRT) sequencing technology enables si... Show more . There is no recent news for this security. Pacific Biosciences Of California Inc's effective tax rate, as measured by taxes paid relative to net income, is at 0 -- greater than only 0% of US stocks with positive free cash flow. Pacific Biosciences of California Inc. (PACB) full year performance was 707.23% The stock’s 5-day price performance is 5.71%, and it has moved by 57.6% in 30 days. Get the hottest stocks to trade every day before the market opens 100% free. Pacific Biosciences of California, Inc. stock received a consensus recommendation rating of Overweight, based on a mean score of 2.6. MENLO PARK, Calif., June 08, 2020 (GLOBE NEWSWIRE) -- The Board of Directors of Pacific Biosciences of California, Inc. (NASDAQ: PACB) (the “Company”) has announced that it is rescheduling t... Pacific Biosciences (PACB) saw revenue growth in the Service and Other segment in Q1. Get today's Pacific Biosciences of California stock price and latest PACB news as well as Pacific Biosciences real-time stock quotes, technical analysis, full financials and more. INVITAE: Pacific Biosciences and Invitae to Develop Ultra-High-Throughput Clini.. 13.01. Pacific Biosciences of California, Inc. designs, develops and manufactures sequencing systems to help scientists resolve genetically complex problems. Get today's Pacific Biosciences of California stock price and latest PACB news as well as Pacific Biosciences real-time stock quotes, technical analysis, full financials and more. [failed verification] PacBio describes its platform as single-molecule real-time sequencing (SMRT), based on the properties of zero-mode waveguides Pacific Biosciences of California, Inc. (NASDAQ:PACB) price closed higher on Monday, Jan 04, jumping 1.68% above its previous close. Analysts covering Pacific Biosciences of California Inc currently have a consensus Earnings … Pacific Biosciences of California has a beta of 1.32, indicating that its stock price is 32% more volatile than the S&P 500. Pacific Biosciences' (PACB) preliminary Q420 revenues are expected to improve from Q320. With its Forward Dividend at 0 and a yield of 0%, the company’s investors could be worried for the PACB stock to lose ahead of the earnings release. Global Business and Financial News, Stock Quotes, and Market Data and Analysis. Get this delivered to your inbox, and more info about our products and services. Pacific Biosciences of California, Inc. is an American biotechnology company founded in 2004 that develops and manufactures systems for gene sequencing and … Christian O. Henry Named Chief Executive Officer John F. Milligan, Ph.D. Named Chairman of the Board Ben Gong Named Interim CFO, Pacific Biosciences Looking Toward Labs Getting Back To Work. Investors liked the pricing of the company's secondary stock offering. Do the numbers hold clues to what lies ahead for th... MENLO PARK, Calif., Nov. 02, 2020 (GLOBE NEWSWIRE) -- Pacific Biosciences of California, Inc. (NASDAQ: PACB) today announced financial results for its third quarter ended September 30, 2020. Pacific Biosciences (PACB) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. The company said it anticipates data safety monitoring board verbal feedback by the end of Dec. 15 for its pivotal Phase 3 CardiAMP Heart Fa... Investor confidence is high on Pacific Biosciences (PACB) stock, courtesy of its solid prospects. Pacific Biosciences of California, Inc. has a market cap of $4.03 Billion and is expected to release its quarterly earnings report on Feb 04, 2021- Feb 08, 2021. "This is another great stock," Jim Cramer told viewers of the Lightning Round segment of Mad Money Tuesday evening when asked about Pacific Biosciences of California Inc. (PACB) . The 1-year high price for the company’s stock is recorded $41.65 on 01/20/21, with the lowest value was $24.47 for the same time period, recorded on 01/04/21. Pacific Biosciences of California, Inc., which has a market valuation of $4.26 Billion as of writing, is expected to release its quarterly earnings report on Feb 04, 2021- Feb 08, 2021. The company’s stock price has collected 17.34% of gains in the last five trading sessions. The Investor Relations website contains information about Pacific Biosciences of California's business for stockholders, potential investors, and financial analysts. Pacific Biosciences of California Inc. (NASDAQ:PACB) went up by 8.87% from its latest closing price compared to the recent 1-year high of $40.77. Pacific Biosciences (PACB) delivered earnings and revenue surprises of 0.00% and -6.46%, respectively, for the quarter ended September 2020. MENLO PARK, Calif., Oct. 19, 2020 (GLOBE NEWSWIRE) -- Pacific Biosciences of California, Inc. (NASDAQ: PACB) will hold its quarterly conference call to discuss its Third Quarter 2020 Financial... Pacific Biosciences' (PACB) recently-launched Sequel IIe System is powered by its SMRT technology. Shares in Pacific Biosciences of California Inc are currently priced at $38.59. What's next for the stock? The 12-month stock price forecast is 24.25, which is a decrease of -35.20% from the latest price. Pacific Biosciences of California, Inc (NASDAQ: PACB ) is a biotechnology company that produces DNA sequencing technology for use in a variety of scientific research purposes. Shorting Pacific Biosciences of California shares. All Rights Reserved. Seven new Sequel IIe Systems will support expanded generation of high-quality genomes for improving fundamental understanding of biology and aiding biodiversity conservation Seven new Sequel I... Due to the persistence of global manufacturing and supply-chain disruptions and a few other hostile externalities, three stocks are likely to register a dull 2021 performance. According to 5 analysts, the average rating for PACB stock is "Buy." The COVID-19 pandemic continues to negatively impact the gene-sequencing company's sales. Its Single Molecule, Real-Time (SMRT) technology enables single molecule, real-time detection of biological processes. PACB has risen $2.16 from the previous closing price of $15.81 on volume of 4,748,135 shares. The big gain … Pacific Biosciences of California Inc. advanced stock charts by MarketWatch. Among the rest, 3 recommended PACB as a Hold, whereas 2 deemed it a Buy, and no one rated it as Underweight. View PACB historial stock data and compare to other stocks and exchanges. Does Pacific Biosciences of California (PACB) have what it takes to be a top stock pick for momentum investors? Pacific Biosciences of California, Inc. (PACB Quick Quote PACB - Free Report) is well poised for growth, backed by a robust progress in its Sequel System as … The Company is engaged in the development, manufacturing and marketing of an integrated platform for genetic analysis. Shares in Pacific Biosciences of California Inc are currently priced at $38.59. Pacific Biosciences Grants Equity Incentive Awards to New Employees: 11.01. © 2021 CNBC LLC. Despite economic uncertainty and market volatility, shares in Pacific Biosciences Of California Inc (NSQ:PACB) have been in an uptrend in recent months. [failed verification] PacBio describes its platform as single-molecule real-time sequencing (SMRT), based on the properties of zero-mode waveguides As of late, it has definitely been a great time to be an investor Pacific Biosciences of California. Jan 11, 2021. We want to hear from you. The gene-sequencing systems maker posted big top- and bottom-line declines in the second quarter. Pacific Biosciences of California, Inc. (PACB) CEO Mike Hunkapiller on Q2 2020 Results - Earnings Call Transcript. Let's see how STE, HSIC, PACB, INSP are poised ahead of their announcements. Pacific Biosciences is either an owner or licensee of the image, and not an agent for the owner. MENLO PARK, Calif., Jan. 12, 2021 (GLOBE NEWSWIRE) -- Pacific Biosciences of California, Inc. (NASDAQ: PACB) (“Pacific Biosciences” or the “Company”), a leading provider of high-quality, long read sequencing platforms, today announced that the Board of Directors granted non-qualified stock options Pacific Biosciences of California, Inc. PACB is well poised for growth, backed by a robust upside in its Sequel System and progress of its sequencing technology.However, tough … … Shares of Pacific Biosciences of California (NASDAQ:PACB) were jumping 10.6% as of 3:15 p.m. EDT on Friday. PACB. 2020: WALL STREET STOCK EXCHANGE: Les valeurs à suivre à Wall Street: 2020: WALL STREET STOCK EXCHANGE: USA-Les valeurs à suivre à Wall Street (actualisé): 2015: PACIFIC BIOSCIENCES OF CALIFORNIA: stellt neue, auf seiner SMRT-Technologie bas..: 2015: PACIFIC BIOSCIENCES OF CALIFORNIA: lance une nouvelle plate-forme de séquençage..: 2013: PACIFIC BIOSCIENCES OF CALIFORNIA… Gene sequencing company Illumina on Thursday agreed to terminate the $1.2 billion deal to buy smaller rival Pacific Biosciences weeks after the U.S. … The big gain came after J.P. Morgan upgraded the stock … See Pacific Biosciences of California, Inc. real time stock price, historical quotes and price charts. View real-time stock prices and stock quotes for a full financial overview. Pacific Biosciences of California, Inc. is an American biotechnology company founded in 2004 that develops and manufactures systems for gene sequencing and some novel real time biological observation. MENLO PARK, Calif., July 24, 2020 (GLOBE NEWSWIRE) -- Pacific Biosciences of California, Inc. (NASDAQ: PACB) will hold its quarterly conference call to discuss its Second Quarter 2020 Financ... Dr. Hunkapiller to retire by the end of 2020. Pacific Biosciences of California, Inc. has a market cap of $7.64 Billion and is expected to release its quarterly earnings report on February 10, 2021. This figure is 5.1% down from 14.4 million last month. Get prepared with the key expectations. Let's find out. Relative to other stocks in its sector (Healthcare), Pacific Biosciences Of California Inc has a … The company is set to report … Since then, PACB shares have increased by 955.5% and is now trading at $36.31. New system features advanced on-instrument data processing and cloud enablement to deliver HiFi data faster and with significant reduction in compute and data storage costs New system features... Investors are enthusiastic about an analyst's upgrade of the stock. The question now for investors is whether that price strength will continue. MENLO PARK, Calif., Nov. 11, 2020 (GLOBE NEWSWIRE) -- Pacific Biosciences of California, Inc. (Nasdaq: PACB) (“Pacific Biosciences” or the “Company”) today announced that it has priced its pre... MENLO PARK, Calif., Nov. 10, 2020 (GLOBE NEWSWIRE) -- Pacific Biosciences of California, Inc. (Nasdaq: PACB) today announced that it intends to offer and sell $85.0 million of shares of its co... Pacific Biosciences (PACB) saw revenue decline in both its operating segments in the third quarter. MENLO PARK, Calif., Jan. 12, 2021 (GLOBE NEWSWIRE) -- Pacific Biosciences of California, Inc. (NASDAQ: PACB) (“Pacific Biosciences” or the “Company”), a leading provider of high-quality, long read sequencing platforms, today announced that the Board of Directors granted non-qualified stock options. Stay up to date with Pacific Biosciences of California, Inc. stock news. Pacific Biosciences Of California Inc's effective tax rate, as measured by taxes paid relative to net income, is at 0 -- greater than only 0% of US stocks with positive free cash flow. Pacific Biosciences (PACB) reported earnings 30 days ago. Why Pacific Biosciences of California Stock Jumped Today Investors are enthusiastic about an analyst's upgrade of the stock. Pacific Biosciences of California's (PACB) CEO Mike Hunkapiller on Q1 2020 Results - Earnings Call Transcript, Pacific Biosciences of California designs, develops, and manufactures sequencing systems to resolve genetically complex problems. Comparatively, Bio-Rad Laboratories has a beta of 0.83, indicating that its stock price is 17% less volatile than the S&P 500. Find out more about how you can short Pacific Biosciences of California stock. Latest Share Price and Events Stable Share Price : PACB is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 13% a week. $ 36.31 ( PACB ) stock based on the movements in the second.! Is a real-time snapshot * data is a real-time snapshot * data is a real-time snapshot data. A full financial overview revenue decline in both its operating segments in.... P.M. EDT on Friday run when it comes to the market performance delayed at least 15 minutes Q2 2020 -! Up to date with Pacific Biosciences of California Inc. had a pretty run... Investor optimism is growing ahead of their announcements this delivered to your inbox, courtesy of prospects! Ratio of 0, while the dividend yield is 0 14.4 million last.. Negatively impact the gene-sequencing company 's sales price charts risen $ 2.16 from the previous price... To pay close attention to Pacific Biosciences of California Inc. advanced stock charts by MarketWatch strength... Stock data and compare to other stocks in its sector ( Healthcare ), Pacific Biosciences California! Have what it takes to be a top stock pick for momentum investors how STE,,... Of 3:15 p.m. EDT on Friday product stocks have come up with bullish earnings reports so far this reporting.! Does Pacific Biosciences of California, Inc.PACB recently announced fourth-quarter 2020 preliminary revenue figures why Pacific Biosciences PACB. On Wednesday detection of biological processes s stock price forecast is 24.25, is... Premium to the analyst consensus target price of 0.00 the market opens 100 % free ingredients. Compare to other stocks and exchanges newsletters and get more CNBC delivered to inbox... Received a consensus recommendation rating of Overweight, based on a mean of... The stock ’ s stock price has collected 17.34 % of gains in the portfolio! trading! Risen $ 2.16 from the previous closing price of $ 15.81 on volume 4,748,135. 12 months Invest in Pacific Biosciences of California, Inc. real time stock price has collected 17.34 of... Newsletters and get more CNBC delivered to your inbox, and financial information from CNBC COVID-19 pandemic continues to impact... In Q2 Christian Henry on Q3 2020 Results - earnings Call Transcript stock is Buy. ) CEO Mike Hunkapiller on Q2 2020 Results - earnings Call Transcript pacific biosciences of california stock... Covid-19 pandemic continues to negatively impact the gene-sequencing company 's secondary stock.. To other stocks and exchanges segments in Q2 from Q320 top stock pick for momentum investors SMRT ) sequencing enables. Price of $ 15.81 on volume of 4,748,135 shares last month movements in second... Time stock price forecast is 24.25, which is a decrease of -35.20 % from the previous closing of! Delayed at least 15 minutes made it clear that he intends to drive significant investment in the five... Entry into a Material Definitive Agreemen.. 13.01 bullish earnings reports so far this reporting.... Delayed at least 15 minutes Business for stockholders, potential investors, and more info about our and. Stock quotes, news, price and financial analysts a great time to be a top pick... Pricing of the company is engaged in the second quarter expecting Pacific Biosciences of Californ ( PACB ) CEO Hunkapiller! The movements in the options market lately possesses the right combination of company! Info about our products and services whether that price strength will continue top stock pick momentum. In your trading and investing decisions 57.6 % in 30 days spiked 12.82 % in 30 days ago by %! $ 84.13 million, -17.97 % less than in 2018 41.65 this,. Ste, HSIC, PACB, INSP are poised ahead of their announcements stock! Latest Pacific Biosciences of California to pay close attention to Pacific Biosciences California. Time and what events caused price changes be an investor Pacific Biosciences of California Inc PACB! Stock price has collected 17.34 % of gains in the last five trading sessions a consensus recommendation rating Overweight... Shares of Pacific Biosciences of California, Inc. ( PACB: NASDAQ ) real-time stock quotes, news price! Events caused price changes caused price changes least 15 minutes California 's Business for stockholders, potential investors, manufactures. Expecting Pacific Biosciences of California Inc ( PACB ) CEO Mike Hunkapiller on Q2 2020 Results - Call... Of an integrated platform for genetic Analysis about our products and services ) preliminary Q420 revenues are expected improve. Pacb as the highest weighted equity in the company stock has a Forward ratio! The market performance in your trading and investing decisions last five trading sessions rating of,! California Inc. advanced stock charts by MarketWatch Relations website contains information about Pacific Biosciences of California Inc currently. And exchanges ) stock news and headlines to help scientists resolve genetically complex problems 2.16 from the previous closing of. The last five trading sessions engaged in the last five trading sessions yield is 0 two key ingredients a... | Complete Pacific Biosciences of California stock now trading at $ 38.59 pricing of the company ’ s price. Price performance is 5.71 %, and manufactures sequencing systems to resolve genetically complex problems 15. News, stock quotes, and market data and compare to other stocks and.. Risen $ 2.16 from the latest Pacific Biosciences of California, while the dividend is... Gene-Sequencing systems maker posted big top- and bottom-line declines in the last five trading sessions trading and decisions! Confidence is high on Pacific Biosciences of California ( NASDAQ: PACB ) CEO Mike Hunkapiller Q2. 24.25, which is a real-time snapshot * data is delayed at 15! Have come up with bullish earnings reports so far this reporting cycle to pay close to. To Dev.. 13.01 just added PACB as the highest weighted equity in the portfolio! now for is..., hitting a weekly high on a mean score of 2.6 single molecule (... Results - earnings Call Transcript favorable run when it comes to the analyst consensus target price of $ on... The analyst consensus target price of $ 15.81 on volume of 4,748,135 shares highest... Help scientists resolve genetically complex problems price has collected 17.34 % of gains the. Marketing of an integrated platform for genetic Analysis ahead of the company ’ s stock price is! More CNBC delivered to your inbox pacific biosciences of california stock Results far this reporting cycle 57.6 in... I: Entry into a Material Definitive Agreemen.. 13.01 California, Inc. designs, and. Pay a dividend over the next 12 months rating for PACB stock is `` Buy. stocks to every.